Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Cybersecurity (BUG) vs Enveric Biosciences Inc (ENVB) Price & Performance

Global X CybersecurityTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Global X Cybersecurity vs Enveric Biosciences Inc — how do they compare? Global X Cybersecurity trades at $42.42, while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Global X Cybersecurity is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

BUGENVB
Sector
Sector/ThematicHealth
52-Week High
$41.99$17.40
52-Week Low
$23.30$1.28
Market Cap
$5.32M
Enterprise Value
$408.82K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Cybersecurity

BUG trades at $39.64, up 0.69% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces resistance near $40 and support at $39. Recent news highlights strong cybersecurity sector tailwinds, with global spending exceeding $300 billion in 2026, though the ETF faces competition from semiconductor-focused alternatives.

Outlook remains positive given cybersecurity's essential role in AI-driven cloud expansion, but valuation premiums and sector competition pose risks. The stock's performance hinges on continued enterprise budget growth and its ability to maintain relevance against disruptive AI technologies.

Enveric Biosciences Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Cybersecurity

BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.

Read more on BUG

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB